Modeling fusion gene-associated sarcoma: Advantages for understanding sarcoma biology and pathology

Pathol Int. 2021 Oct;71(10):643-654. doi: 10.1111/pin.13142. Epub 2021 Jul 15.

Abstract

Disease-specific gene fusions are reportedly major driver mutations in approximately 30% of bone and soft tissue sarcomas. Most fusion genes encode transcription factors or co-factors that regulate downstream target genes, altering cell growth, lineage commitment, and differentiation. Given the limitations of investigating their functions in vitro, the generation of mouse models expressing fusion genes in the appropriate cellular lineages is pivotal. Therefore, we generated a series of mouse models by introducing fusion genes into embryonic mesenchymal progenitors. This review describes mouse models of Ewing, synovial, alveolar soft part, and CIC-rearranged sarcomas. Furthermore, we describe the similarities between these models and their human counterparts. These models provide remarkable advantages to identify cells-of-origin, specific collaborators of fusion genes, angiogenesis key factors, or diagnostic biomarkers. Finally, we discuss the relationship between fusion proteins and the epigenetic background as well as the possible role of the super-enhancers.

Keywords: CIC-rearranged sarcoma; Ewing sarcoma; alveolar soft part sarcoma; angiogenesis; cell-of-origin; fusion gene; mouse model; super-enhancer; synovial sarcoma.

Publication types

  • Review

MeSH terms

  • Animals
  • Biomarkers, Tumor / genetics*
  • Biomarkers, Tumor / metabolism
  • Bone Neoplasms / genetics*
  • Bone Neoplasms / metabolism
  • Bone Neoplasms / pathology
  • Humans
  • Mice
  • Oncogene Fusion*
  • Oncogene Proteins, Fusion / genetics*
  • Oncogene Proteins, Fusion / metabolism
  • Sarcoma / genetics*
  • Sarcoma / metabolism
  • Sarcoma / pathology
  • Soft Tissue Neoplasms / genetics*
  • Soft Tissue Neoplasms / metabolism
  • Soft Tissue Neoplasms / pathology

Substances

  • Biomarkers, Tumor
  • Oncogene Proteins, Fusion